Skip to Content
Merck
All Photos(1)

Documents

SML3050

Sigma-Aldrich

Olsalazine sodium

Synonym(s):

Olsalazine sodium, 3,3´-Azobis(6-hydroxybenzoic acid) sodium, 5,5′-Azodisalicylic acid sodium, 5,5′-azobis(salicylic acid) sodium, C.I. Mordant Yellow 5; 3,3′-dicarboxy-4,4′-dihydroxyazobenzene sodium, azodisal sodium

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H8N2O6 · 2Na
CAS Number:
6054-98-4
Molecular Weight:
346.20
UNSPSC Code:
12352200
NACRES:
NA.24

Assay

≥98% (HPLC)

Quality Level

100

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

Olsalazine is an anti-inflammatory drug used in inflammatory bowel disease and ulcerative colitis treatments. It is a pro-drug of 5-aminosalicylic acid (mesalamine) that it is converted by the bacteria in the colon to mesalamine. Olsalazine (5-aminosalicylic acid) is consider as a broad-spectrum anticancer agent. Additionally, olsalazine increases both eEF1A2 and utrophin A levels in in C2C12 myoblasts (relevant to Duchenne muscular dystrophy).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sandra Cortez-Maya et al.
Biomolecules, 9(8) (2019-08-16)
Improving the activity and selectivity profile of anticancer agents will require designing drug carrier systems that employ soluble macromolecules. Olsalazine-PAMAM-dendrimer-salicylic acid-conjugates with dendritic arms of different lengths have shown good stability regarding the chemical link between drug and spacer. In
Amany A Abdin et al.
Journal of Crohn's & colitis, 2(4), 296-303 (2008-12-01)
Traditional medical treatments for ulcerative colitis (UC) are still compromised by its adverse effects and not potent enough to keep in remission for long-term periods. So, new therapies that are targeted at specific disease mechanisms have the potential to provide

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service